Sectors
CRVO
CervoMed Inc.
3.55
1 x 2.56
2 x 4.48
bid
ask
-
0.14
3.79%
2 @ 04:00 PM
3.53 -0.02 (0.56%)
| Ytd | -55.06% | |
| 1y | -36.15% |
3.45
day range
3.69
2.13
52 week range
13.13
| Open | 3.64 | Prev Close | 3.69 | Low | 3.45 | High | 3.69 | Mkt Cap | 32.87M |
| Vol | 310.12K | Avg Vol | 5.57M | EPS | -3.26 | P/E | N/A | Forward P/E | -0.87 |
| Beta | N/A | Short Ratio | 15.72 | Inst. Own | 42.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 3.40 | 200-d Avg | 5.74 | 1yr Est | 20.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.41 | -0.55 | -0.14 | -34.15% |
| 2024-08-09 | 2024-06 | -0.24 | -0.27 | -0.03 | -12.50% |
| 2024-05-14 | 2024-03 | -0.46 | -0.41 | 0.05 | 10.87% |
| 2024-04-01 | 2023-12 | -0.95 | N/A | N/A | N/A |
| 2023-11-13 | 2023-09 | -0.95 | -0.7 | 0.25 | 26.32% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-17 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2024-12-11 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2024-12-11 | Chardan Capital | Downgrade | Buy | Neutral |
| 2024-12-10 | Jones Trading | Downgrade | Buy | Hold |
| 2024-12-10 | D. Boral Capital | Downgrade | Buy | Hold |
| 2024-12-05 | HC Wainwright & Co. | Upgrade | Buy |
Profile
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-11-08 | ALAM JOHN J | Chief Executive Officer | 1.46M | Stock Gift |
| 2024-02-25 | BOGER JOSHUA S | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2023-01-30 | COBUZZI ROBERT JOSEPH JR | Chief Executive Officer | 1.62K | Conversion of Exercise of derivative security |
| 2024-08-26 | ELDER WILLIAM ROBERT | General Counsel | 1.27K | Purchase |
| 2023-11-08 | GREGOIRE SYLVIE L | Director and Beneficial Owner of more than 10% of a Class of Security | 1.46M | Stock Gift |
| 2023-08-30 | HOLLINGSWORTH JANE H | Director | 898.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | RA Capital Management, L.P. | 817.12K | 1.81M | 9.90% |
| 2024-09-29 | AWM Investment Company, Inc. | 449.01K | 992.30K | 5.44% |
| 2024-09-29 | Armistice Capital, LLC | 402.00K | 888.42K | 4.87% |
| 2024-09-29 | Vanguard Group Inc | 400.30K | 884.66K | 4.85% |
| 2024-09-29 | Blackrock Inc. | 318.77K | 704.47K | 3.86% |
| 2024-09-29 | Ikarian Capital, LLC | 202.35K | 447.18K | 2.45% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 263.00K | 581.23K | 3.19% |
| 2024-10-30 | iShares Russell 2000 ETF | 127.94K | 282.76K | 1.55% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 89.79K | 198.43K | 1.09% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 55.40K | 122.44K | 0.67% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 48.05K | 106.19K | 0.58% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 25.89K | 57.22K | 0.31% |